Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-specific cytokine-secreting TCR-T cells
- Development stage
- Unknown
- Lead developer
- Xinqiao Hospital
- Modality
- Vaccines & Immunotherapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EBV-specific cytokine-secreting TCR-T cells represent an engineered T-cell therapy designed to target Epstein-Barr virus (EBV)-positive cancers, such as nasopharyngeal carcinoma. These T cells are genetically modified to express a T-cell receptor (TCR) that specifically recognizes EBV-derived epitopes presented on the surface of infected cancer cells. A key feature of this therapy is the incorporation of a cytokine-secretion element, which enables the engineered T cells to release cytokines. This cytokine secretion is intended to enhance the anti-tumor immune response by activating both innate immune cells (like NK cells) and other adaptive immune cells, thereby helping to overcome the immunosuppressive tumor microenvironment often found in solid cancers and improving therapeutic efficacy.
- Other names
- LMP2 antigen-specific TCR T cellsLMP-2 antigen-specific TCR T cellsLMP 2 antigen-specific TCR T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)Epstein-Barr virus latent membrane protein 2-derived peptide–HLA class I complex
Beyond the preview
Go deeper on EBV-specific cytokine-secreting TCR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-specific cytokine-secreting TCR-T cells.